Creative Medical Technologies is a commercial-stage biotechnology company developing regenerative therapies based on stem and immune cells for indications in immunotherapy, endocrinology, urology, neurology, and orthopedics. The company operates through multiple wholly-owned subsidiaries and pursues a dual commercialization strategy: autologous cell therapies (derived from the patient's own cells) such as StemSpine and OvaStem are offered directly through physician offices and exempt from FDA premarket approval, while allogeneic therapies such as AlloStem and ImmCelz require FDA approval through standard clinical trial pathways. The company generates revenue through therapy sales, licensing partnerships with biotechnology collaborators, and regulatory exclusivity; its primary markets span chronic pain, Type 1 and Type 2 diabetes, female infertility, and immune disorders.